CML Partnership 091012d

Article

You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.

 

You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.

If you do not wish to leave this site, click Cancel. Or, click OK to continue.

Cancel

OK >

Treatment of Ph+ CML

Advancing Science

Advancing Care

Future goals for Ph+ CML patients are being shaped by an actively evolving paradigm.

Stay up to date with these interactive assets.

Explore the evolution
of Ph+ CML care

Find out more about early
therapies, important milestones,
and the new era of advanced care

Learn more >

A guide to read and interpret IS RQ-PCR reports

Learn how IS RQ-PCR results track progress and inform treatment decisions

The importance of the International Scale for RQ-PCR

A deeper look at why the International Scale is used to standardize results

Watch a new video on Ph+ CML care

The mechanism of the disease provides a crucial learning for treating Ph+ CML

Maecenas non auctor est. Aliquam erat

Donec convallis arcu id purus gravida volutpat consectetur sit amet nisi. Nulla in massa.

For information about a free trial of IS RQ-PCR, call MolecularMD at 877-459-4979 or
Genoptix at 800-755-1605 and ask about GET RQ-PCR NOW.

To learn more about Ph+ CML treatment options, click here.

Glossary

AP=accelerated phase. BC=blast crisis. BCR-ABL=breakpoint cluster region-abelson. Ph+ CML=Philadelphia chromosome–positive chronic myeloid leukemia. CBC=complete blood count. CHR=complete hematologic response. mCyR=major cytogenic response. PCyR=partial cytogenetic response. CCyR=complete cytogenetic response. FISH=fluorescence in situ hybridization. ELN=European Leukemia Net. MMR=major molecular response. MR=molecular response. MRD=minimal residual disease. NCCN=National Comprehensive Cancer Network. IS=International Scale. RQ-PCR=real-time quantitative polymerase chain reaction. TKI=tyrosine kinase inhibitor.

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080 © 2012 Novartis 08/12 T-CDE-1047709

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.